Editas Medicine (EDIT) Retained Earnings (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Retained Earnings of -$1.6 billion for Q4 2025, down 10.9% year-over-year from -$1.8 billion in Q4 2024, and little changed quarter-over-quarter from -$1.6 billion in Q3 2025.
Editas Medicine (EDIT) Retained Earnings (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Retained Earnings for 11 consecutive years, with -$1.6 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings fell 10.9% year-over-year to -$1.6 billion; the TTM figure through Dec 2025 stood at -$1.6 billion (down 10.9% YoY), while the FY2025 annual figure was -$1.6 billion, down 10.9% from the prior year.
- Retained Earnings was little changed at -$1.6 billion in Q4 2025 per EDIT's latest filing, from -$1.6 billion in the prior quarter.
- Across five years, Retained Earnings topped out at -$721.9 million in Q1 2021 and bottomed at -$1.6 billion in Q4 2025.
- Historically, Retained Earnings has averaged -$1.2 billion across 5 years, with a median of -$1.2 billion in 2023.
- Annual changes were most pronounced in 2021 — Retained Earnings slumped 35.44% — and 2025, when it retreated 10.9%.
- Editas Medicine's Retained Earnings stood at -$857.7 million in 2021, then slipped by 25.7% to -$1.1 billion in 2022, then fell by 14.21% to -$1.2 billion in 2023, then slipped by 19.25% to -$1.5 billion in 2024, then declined by 10.9% to -$1.6 billion in 2025.
- Business Quant data shows EDIT's Retained Earnings at -$1.6 billion in Q4 2025, -$1.6 billion in Q3 2025, and -$1.6 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | -1.63 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.63 Bn |
| Sep 30, 2025 | -1.62 Bn |
| Jun 30, 2025 | -1.60 Bn |
| Mar 31, 2025 | -1.54 Bn |
| Dec 31, 2024 | -1.47 Bn |
| Sep 30, 2024 | -1.42 Bn |
| Jun 30, 2024 | -1.40 Bn |
| Mar 31, 2024 | -1.30 Bn |
| Dec 31, 2023 | -1.23 Bn |
| Sep 30, 2023 | -1.21 Bn |
| Jun 30, 2023 | -1.20 Bn |
| Mar 31, 2023 | -1.13 Bn |
| Dec 31, 2022 | -1.08 Bn |
| Sep 30, 2022 | -1.02 Bn |
| Jun 30, 2022 | -961.70 Mn |
| Mar 31, 2022 | -908.21 Mn |
| Dec 31, 2021 | -857.70 Mn |
| Sep 30, 2021 | -816.30 Mn |
| Jun 30, 2021 | -777.20 Mn |
| Mar 31, 2021 | -721.93 Mn |